prostate cancer
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Part; - Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases; - Written informed consent; - At least 2 metastases in the thorax per patient detected by conventional imaging (e.g., bone scan, either CT or MRI of the chest, abdomen and pelvis); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan); - At least one tumour (metastasis) with diameter * 1.5 cm (to minimize partial volume effects); - Patients able to remain supine for 60 minutes in the PET-CT scanner;;Part B; - Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases; - Written informed consent; - At least one tumour (metastasis) with diameter >1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan); - Patients able to remain supine for 80 minutes in the PET-CT scanner;
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Claustrophobia (part A and B); - Multiple malignancies (part A and B); - Participation part A (Part B)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A A pharmacokinetic model for [18F]PSMA and an appropriate simplified quantitative method. Part B Test-retest variability of the simplified method of choice (part A) implemented in dynamic thoracic and WB [18F]PSMA PET/CT. | — |
Countries
Netherlands
Outcome results
None listed